Mesoblast Limited (MESO) announced Monday that its recently launched cell therapy is showing promising results in the real world, with most young patients surviving a serious complication that can occur after bone marrow transplants.
The therapy, called Ryoncil, became commercially available in March 2025 as the first mesenchymal stromal cell product ever approved by the FDA for any condition. It's designed to treat steroid-refractory acute graft-versus-host disease in children as young as 2 months old.
That's a mouthful, so here's what it means: After some kids receive bone marrow transplants, the donated immune cells attack their body instead of protecting it. Doctors typically treat this with high-dose steroids, but when that doesn't work after a week or the condition gets worse after three days, it's classified as steroid-refractory. At that point, options become limited and the situation turns dire.
The Early Numbers Look Solid
Among the first 25 patients treated with Ryoncil since launch, 21 survived and completed the full 28-day treatment regimen outlined in the FDA approval. That's an 84% survival rate in a population facing a life-threatening condition.
The four patients who didn't make it had already tried and failed other therapies before receiving Ryoncil, and they died from severe disease within 28 days. This underscores what Mesoblast is now emphasizing: getting patients on Ryoncil as early as possible after steroids fail, rather than using it as a last resort after everything else has been exhausted.
The data aligns with what the company saw in clinical trials, which is always reassuring when a drug moves from controlled studies into messy reality.
Building Out the Infrastructure
Rolling out a specialized cell therapy isn't like launching a pill you can ship to any pharmacy. Mesoblast has been methodically onboarding transplant centers, and it's made solid progress. The company has brought 45 centers online so far, with a target of 64 centers that collectively perform 94% of transplants in the U.S.
On the insurance front, Ryoncil already has coverage extending to over 260 million Americans. That includes Federal Medicaid through the Centers for Medicare & Medicaid Services and mandatory fee-for-service Medicaid coverage across all states.
A significant milestone came on October 1, 2025, when CMS issued a specific Healthcare Common Procedure Coding System J-Code for Ryoncil. That might sound bureaucratic and boring, but it matters because it simplifies billing and reimbursement. The result? Greater usage of Ryoncil under CMS coverage versus commercial insurance in the last quarter.
Eyes on a Bigger Prize
The pediatric market is important, but it's not the endgame. Mesoblast is now setting its sights on adults with severe steroid-refractory acute graft-versus-host disease, a market roughly three times larger than the pediatric population.
A pivotal trial in adults is moving forward with the NIH-funded Bone Marrow Transplant Clinical Trials Network, and site enrollment is expected to begin this quarter. If successful, this could significantly expand Ryoncil's commercial opportunity.
The therapy is already delivering financially. Mesoblast reported $35.1 million in gross revenue from Ryoncil for the quarter ended December 31, 2025, representing a 60% sequential jump.
Other Developments
Last week, Mesoblast shared feedback from the FDA regarding a potential Biologics License Application for rexlemestrocel-L, another allogeneic cell therapy candidate. This one targets chronic discogenic low back pain, a completely different indication.
The FDA acknowledged that data from the MSB-DR003 trial showed effects on pain intensity that appear to favor the active treatment over placebo. It's early, but positive regulatory signals are always welcome when you're in the business of developing novel therapies.
Stock Movement: Mesoblast shares were up 1.77% at $19.01 at the time of publication on Tuesday.
